2,936 results on '"Martinez, Fernando J."'
Search Results
2. Local heterogeneity of normal lung parenchyma and small airways disease are associated with COPD severity and progression
- Author
-
Bell, Alexander J., Pal, Ravi, Labaki, Wassim W., Hoff, Benjamin A., Wang, Jennifer M., Murray, Susan, Kazerooni, Ella A., Galban, Stefanie, Lynch, David A., Humphries, Stephen M., Martinez, Fernando J., Hatt, Charles R., Han, MeiLan K., Ram, Sundaresh, and Galban, Craig J.
- Published
- 2024
- Full Text
- View/download PDF
3. PCSK6 and Survival in Idiopathic Pulmonary Fibrosis
- Author
-
Oldham, Justin M, Allen, Richard J, Lorenzo-Salazar, Jose M, Molyneaux, Philip L, Ma, Shwu-Fan, Joseph, Chitra, Kim, John S, Guillen-Guio, Beatriz, Hernández-Beeftink, Tamara, Kropski, Jonathan A, Huang, Yong, Lee, Cathryn T, Adegunsoye, Ayodeji, Pugashetti, Janelle Vu, Linderholm, Angela L, Vo, Vivian, Strek, Mary E, Jou, Jonathan, Muñoz-Barrera, Adrian, Rubio-Rodriguez, Luis A, Hubbard, Richard, Hirani, Nik, Whyte, Moira KB, Hart, Simon, Nicholson, Andrew G, Lancaster, Lisa, Parfrey, Helen, Rassl, Doris, Wallace, William, Valenzi, Eleanor, Zhang, Yingze, Mychaleckyj, Josyf, Stockwell, Amy, Kaminski, Naftali, Wolters, Paul J, Molina-Molina, Maria, Banovich, Nicholas E, Fahy, William A, Martinez, Fernando J, Hall, Ian P, Tobin, Martin D, Maher, Toby M, Blackwell, Timothy S, Yaspan, Brian L, Jenkins, R Gisli, Flores, Carlos, Wain, Louise V, and Noth, Imre
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Lung ,Genetics ,Autoimmune Disease ,Rare Diseases ,Human Genome ,Good Health and Well Being ,Humans ,Genome-Wide Association Study ,Idiopathic Pulmonary Fibrosis ,Proportional Hazards Models ,Europe ,Serine Endopeptidases ,Proprotein Convertases ,IPF ,genome-wide association study ,genomics ,survival ,PCSK6 protein ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by limited treatment options and high mortality. A better understanding of the molecular drivers of IPF progression is needed. Objectives: To identify and validate molecular determinants of IPF survival. Methods: A staged genome-wide association study was performed using paired genomic and survival data. Stage I cases were drawn from centers across the United States and Europe and stage II cases from Vanderbilt University. Cox proportional hazards regression was used to identify gene variants associated with differential transplantation-free survival (TFS). Stage I variants with nominal significance (P
- Published
- 2023
4. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Fortis, Spyridon, Quibrera, Pedro M, Comellas, Alejandro P, Bhatt, Surya P, Tashkin, Donald P, Hoffman, Eric A, Criner, Gerard J, Han, MeiLan K, Barr, R Graham, Arjomandi, Mehrdad, Dransfield, Mark B, Peters, Stephen P, Dolezal, Brett A, Kim, Victor, Putcha, Nirupama, Rennard, Stephen I, Paine, Robert, Kanner, Richard E, Curtis, Jeffrey L, Bowler, Russell P, Martinez, Fernando J, Hansel, Nadia N, Krishnan, Jerry A, Woodruff, Prescott G, Barjaktarevic, Igor Z, Couper, David, Anderson, Wayne H, Cooper, Christopher B, Investigators, Subpopulations and Intermediate Outcome Measures in COPD Study, Alexis, Neil E, Barjaktarevic, Igor, Basta, Patricia, Bateman, Lori A, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Couper, David J, Crystal, Ronald G, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hastie, Annette T, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Wells, J Michael, and Wise, Robert A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Lung ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Good Health and Well Being ,Humans ,Bronchodilator Agents ,Nicotiana ,Retrospective Studies ,Forced Expiratory Volume ,Pulmonary Disease ,Chronic Obstructive ,Asthma ,Vital Capacity ,bronchodilator ,bronchodilator response ,bronchodilator responsiveness ,bronchodilator reversibility ,COPD ,Subpopulations and Intermediate Outcome Measures in COPD Study Investigators ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundBronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features.Research questionIs consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD?Study design and methodsWe retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV1 (FEV1-BDR), change in FVC (FVC-BDR), and change in in FEV1, FVC or both (ATS-BDR). Using generalized linear models adjusted for demographics, smoking history, FEV1 % predicted after bronchodilator administration, and number of visits that the participant completed, we assessed the association of BDR group: (1) consistent BDR, (2) inconsistent BDR, and (3) never BDR with asthma, CT scan features, blood eosinophil levels, and FEV1 decline in participants without COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 0) and the entire cohort (participants with or without COPD).ResultsBoth consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV1-BDR and FVC-BDR definitions. Eosinophils did not vary consistently among BDR groups. Consistent BDR was associated with FEV1 decline over time relative to never BDR in the entire cohort. In participants with GOLD stage 0 disease, both the inconsistent ATS-BDR group (OR, 3.20; 95% CI, 2.21-4.66; P < .001) and consistent ATS-BDR group (OR, 9.48; 95% CI, 3.77-29.12; P < .001) were associated with progression to COPD relative to the never ATS-BDR group.InterpretationDemonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease.
- Published
- 2023
5. Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts
- Author
-
Adegunsoye, Ayodeji, Newton, Chad A, Oldham, Justin M, Ley, Brett, Lee, Cathryn T, Linderholm, Angela L, Chung, Jonathan H, Garcia, Nicole, Zhang, Da, Vij, Rekha, Guzy, Robert, Jablonski, Renea, Bag, Remzi, Voogt, Rebecca S, Ma, Shwu-Fan, Sperling, Anne I, Raghu, Ganesh, Martinez, Fernando J, Strek, Mary E, Wolters, Paul J, Garcia, Christine Kim, Pierce, Brandon L, and Noth, Imre
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Good Health and Well Being ,Humans ,Pulmonary Fibrosis ,Ethnicity ,Proportional Hazards Models ,Racial Groups ,Telomere ,Leukocytes - Abstract
Pulmonary fibrosis (PF) is characterized by profound scarring and poor survival. We investigated the association of leukocyte telomere length (LTL) with chronological age and mortality across racially diverse PF cohorts. LTL measurements among participants with PF stratified by race/ethnicity were assessed in relation to age and all-cause mortality, and compared to controls. Generalized linear models were used to evaluate the age-LTL relationship, Cox proportional hazards models were used for hazard ratio estimation, and the Cochran-Armitage test was used to assess quartiles of LTL. Standardized LTL shortened with increasing chronological age; this association in controls was strengthened in PF (R = -0.28; P
- Published
- 2023
6. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
- Author
-
Ghosh, Auyon J, Hobbs, Brian D, Yun, Jeong H, Saferali, Aabida, Moll, Matthew, Xu, Zhonghui, Chase, Robert P, Morrow, Jarrett, Ziniti, John, Sciurba, Frank, Barwick, Lucas, Limper, Andrew H, Flaherty, Kevin, Criner, Gerard, Brown, Kevin K, Wise, Robert, Martinez, Fernando J, McGoldrick, Daniel, Cho, Michael H, DeMeo, Dawn L, Silverman, Edwin K, Castaldi, Peter J, and Hersh, Craig P
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Genetics ,Rare Diseases ,Chronic Obstructive Pulmonary Disease ,Orphan Drug ,Autoimmune Disease ,Lung ,Aetiology ,2.1 Biological and endogenous factors ,Respiratory ,Humans ,Idiopathic Pulmonary Fibrosis ,Pulmonary Disease ,Chronic Obstructive ,Sequence Analysis ,RNA ,Transcriptome ,COPD ,IPF ,RNA sequencing ,NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundChronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are characterized by shared exposures and clinical features, but distinct genetic and pathologic features exist. These features have not been well-studied using large-scale gene expression datasets. We hypothesized that there are divergent gene, pathway, and cellular signatures between COPD and IPF.MethodsWe performed RNA-sequencing on lung tissues from individuals with IPF (n = 231) and COPD (n = 377) compared to control (n = 267), defined as individuals with normal spirometry. We grouped the overlapping differential expression gene sets based on direction of expression and examined the resultant sets for genes of interest, pathway enrichment, and cell composition. Using gene set variation analysis, we validated the overlap group gene sets in independent COPD and IPF data sets.ResultsWe found 5010 genes differentially expressed between COPD and control, and 11,454 genes differentially expressed between IPF and control (1% false discovery rate). 3846 genes overlapped between IPF and COPD. Several pathways were enriched for genes upregulated in COPD and downregulated in IPF; however, no pathways were enriched for genes downregulated in COPD and upregulated in IPF. There were many myeloid cell genes with increased expression in COPD but decreased in IPF. We found that the genes upregulated in COPD but downregulated in IPF were associated with lower lung function in the independent validation cohorts.ConclusionsWe identified a divergent gene expression signature between COPD and IPF, with increased expression in COPD and decreased in IPF. This signature is associated with worse lung function in both COPD and IPF.
- Published
- 2022
7. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
- Author
-
Han, MeiLan K, Ye, Wen, Wang, Di, White, Emily, Arjomandi, Mehrdad, Barjaktarevic, Igor Z, Brown, Stacey-Ann, Buhr, Russell G, Comellas, Alejandro P, Cooper, Christopher B, Criner, Gerard J, Dransfield, Mark T, Drescher, Frank, Folz, Rodney J, Hansel, Nadia N, Kalhan, Ravi, Kaner, Robert J, Kanner, Richard E, Krishnan, Jerry A, Lazarus, Stephen C, Maddipati, Veeranna, Martinez, Fernando J, Mathews, Anne, Meldrum, Catherine, McEvoy, Charlene, Nyunoya, Toru, Rogers, Linda, Stringer, William W, Wendt, Christine H, Wise, Robert A, Wisniewski, Stephen R, Sciurba, Frank C, and Woodruff, Prescott G
- Subjects
Lung ,Tobacco ,Clinical Research ,Clinical Trials and Supportive Activities ,Tobacco Smoke and Health ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Good Health and Well Being ,Adrenergic beta-2 Receptor Agonists ,Anti-Bacterial Agents ,Bronchodilator Agents ,Forced Expiratory Volume ,Glucocorticoids ,Glycopyrrolate ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Treatment Outcome ,RETHINC Study Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundMany persons with a history of smoking tobacco have clinically significant respiratory symptoms despite an absence of airflow obstruction as assessed by spirometry. They are often treated with medications for chronic obstructive pulmonary disease (COPD), but supporting evidence for this treatment is lacking.MethodsWe randomly assigned persons who had a tobacco-smoking history of at least 10 pack-years, respiratory symptoms as defined by a COPD Assessment Test score of at least 10 (scores range from 0 to 40, with higher scores indicating worse symptoms), and preserved lung function on spirometry (ratio of forced expiratory volume in 1 second [FEV1] to forced vital capacity [FVC] ≥0.70 and FVC ≥70% of the predicted value after bronchodilator use) to receive either indacaterol (27.5 μg) plus glycopyrrolate (15.6 μg) or placebo twice daily for 12 weeks. The primary outcome was at least a 4-point decrease (i.e., improvement) in the St. George's Respiratory Questionnaire (SGRQ) score (scores range from 0 to 100, with higher scores indicating worse health status) after 12 weeks without treatment failure (defined as an increase in lower respiratory symptoms treated with a long-acting inhaled bronchodilator, glucocorticoid, or antibiotic agent).ResultsA total of 535 participants underwent randomization. In the modified intention-to-treat population (471 participants), 128 of 227 participants (56.4%) in the treatment group and 144 of 244 (59.0%) in the placebo group had at least a 4-point decrease in the SGRQ score (difference, -2.6 percentage points; 95% confidence interval [CI], -11.6 to 6.3; adjusted odds ratio, 0.91; 95% CI, 0.60 to 1.37; P = 0.65). The mean change in the percent of predicted FEV1 was 2.48 percentage points (95% CI, 1.49 to 3.47) in the treatment group and -0.09 percentage points (95% CI, -1.06 to 0.89) in the placebo group, and the mean change in the inspiratory capacity was 0.12 liters (95% CI, 0.07 to 0.18) in the treatment group and 0.02 liters (95% CI, -0.03 to 0.08) in the placebo group. Four serious adverse events occurred in the treatment group, and 11 occurred in the placebo group; none were deemed potentially related to the treatment or placebo.ConclusionsInhaled dual bronchodilator therapy did not decrease respiratory symptoms in symptomatic, tobacco-exposed persons with preserved lung function as assessed by spirometry. (Funded by the National Heart, Lung, and Blood Institute and others; RETHINC ClinicalTrials.gov number, NCT02867761.).
- Published
- 2022
8. Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.
- Author
-
Baugh, Aaron, Buhr, Russell G, Quibrera, Pedro, Barjaktarevic, Igor, Barr, R Graham, Bowler, Russell, Han, Meilan King, Kaufman, Joel D, Koch, Abigail L, Krishnan, Jerry, Labaki, Wassim, Martinez, Fernando J, Mkorombindo, Takudzwa, Namen, Andrew, Ortega, Victor, Paine, Robert, Peters, Stephen P, Schotland, Helena, Sundar, Krishna, Zeidler, Michelle R, Hansel, Nadia N, Woodruff, Prescott G, and Thakur, Neeta
- Subjects
Sleep Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Behavioral and Social Science ,Respiratory ,Good Health and Well Being ,Disease Progression ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Severity of Illness Index ,Sleep Quality ,Sleep Wake Disorders ,sleep quality ,PSQI ,exacerbations ,COPD ,health disparities ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery - Abstract
Study objectivesSleep is an important dimension in the care of chronic obstructive pulmonary disease (COPD), but its relevance to exacerbations is unclear. We wanted to assess whether sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI) is associated with an increased risk of COPD exacerbations and does this differ by socio-environmental exposures.MethodsWe included 1647 current and former smokers with spirometrically confirmed COPD from the SPIROMICS cohort. We assessed incidence rate ratios for exacerbation using zero-inflated negative binomial regression adjusting for demographics, medical comorbidities, and multiple metrics of disease severity, including respiratory medications, airflow obstruction, and symptom burden. Our final model adjusted for socio-environmental exposures using the Area Deprivation Index, a composite measure of contemporary neighborhood quality, and Adversity-Opportunity Index, a composite measure of individual-level historic and current socioeconomic indicators. We used a pre-determined threshold of 20% missingness to undertake multiple imputation by chained equations. As sensitivity analyses, we repeated models in those with complete data and after controlling for prior exacerbations. As an exploratory analysis, we considered an interaction between socio-environmental condition and sleep quality.ResultsAfter adjustment for all co-variates, increasing PSQI scores (range 0-21) were associated with a 5% increased risk for exacerbation per point (p = .001) in the imputed dataset. Sensitivity analyses using complete cases and after controlling for prior exacerbation history were similar. Exploratory analysis suggested less effect among those who lived in poor-quality neighborhoods (p-for-interaction = .035).ConclusionsPoor sleep quality may contribute to future exacerbations among patients with COPD. This represents one target for improving disease control.Clinical trial registrationSubpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). ClinicalTrials.gov Identifier# NCT01969344. Registry URL: https://clinicaltrials.gov/ct2/show/.
- Published
- 2022
9. Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR
- Author
-
Belz, Daniel C, Woo, Han, Putcha, Nirupama, Paulin, Laura M, Koehler, Kirsten, Fawzy, Ashraf, Alexis, Neil E, Barr, R Graham, Comellas, Alejandro P, Cooper, Christopher B, Couper, David, Dransfield, Mark, Gassett, Amanda J, Han, MeiLan, Hoffman, Eric A, Kanner, Richard E, Krishnan, Jerry A, Martinez, Fernando J, Paine, Robert, Peng, Roger D, Peters, Stephen, Pirozzi, Cheryl S, Woodruff, Prescott G, Kaufman, Joel D, Hansel, Nadia N, and Investigators, SPIROMICS
- Subjects
Epidemiology ,Public Health ,Health Sciences ,Climate-Related Exposures and Conditions ,Behavioral and Social Science ,Lung ,Clinical Research ,Health Disparities ,Chronic Obstructive Pulmonary Disease ,Respiratory ,No Poverty ,Air Pollutants ,Air Pollution ,Cohort Studies ,Environmental Exposure ,Humans ,Middle Aged ,Ozone ,Poverty ,Pulmonary Disease ,Chronic Obstructive ,Smokers ,Air pollution ,Chronic obstructive pulmonary disease ,Socioeconomic factors ,Poverty areas ,SPIROMICS Investigators ,Environmental Sciences - Abstract
BackgroundNeighborhood poverty has been associated with poor health outcomes. Previous studies have also identified adverse respiratory effects of long-term ambient ozone. Factors associated with neighborhood poverty may accentuate the adverse impact of ozone on respiratory health.ObjectivesTo evaluate whether neighborhood poverty modifies the association between ambient ozone exposure and respiratory morbidity including symptoms, exacerbation risk, and radiologic parameters, among participants of the SPIROMICS AIR cohort study.MethodsSpatiotemporal models incorporating cohort-specific monitoring estimated 10-year average outdoor ozone concentrations at participants' homes. Adjusted regression models were used to determine the association of ozone exposure with respiratory outcomes, accounting for demographic factors, education, individual income, body mass index (BMI), and study site. Neighborhood poverty rate was defined by percentage of families living below federal poverty level per census tract. Interaction terms for neighborhood poverty rate with ozone were included in covariate-adjusted models to evaluate for effect modification.Results1874 participants were included in the analysis, with mean (± SD) age 64 (± 8.8) years and FEV1 (forced expiratory volume in one second) 74.7% (±25.8) predicted. Participants resided in neighborhoods with mean poverty rate of 9.9% (±10.3) of families below the federal poverty level and mean 10-year ambient ozone concentration of 24.7 (±5.2) ppb. There was an interaction between neighborhood poverty rate and ozone concentration for numerous respiratory outcomes, including COPD Assessment Test score, modified Medical Research Council Dyspnea Scale, six-minute walk test, and odds of COPD exacerbation in the year prior to enrollment, such that adverse effects of ozone were greater among participants in higher poverty neighborhoods.ConclusionIndividuals with COPD in high poverty neighborhoods have higher susceptibility to adverse respiratory effects of ambient ozone exposure, after adjusting for individual factors. These findings highlight the interaction between exposures associated with poverty and their effect on respiratory health.
- Published
- 2022
10. A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis
- Author
-
Pugashetti, Janelle Vu, Kim, John S., Combs, Michael P., Ma, Shwu-Fan, Adegunsoye, Ayodeji, Linderholm, Angela L., Strek, Mary E., Chen, Ching-Hsien, Dilling, Daniel F., Whelan, Timothy P.M., Flaherty, Kevin R., Martinez, Fernando J., Noth, Imre, and Oldham, Justin M.
- Published
- 2024
- Full Text
- View/download PDF
11. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD
- Author
-
Esther, Charles R, O’Neal, Wanda K, Anderson, Wayne H, Kesimer, Mehmet, Ceppe, Agathe, Doerschuk, Claire M, Alexis, Neil E, Hastie, Annette T, Barr, R Graham, Bowler, Russell P, Wells, J Michael, Oelsner, Elizabeth C, Comellas, Alejandro P, Tesfaigzi, Yohannes, Kim, Victor, Paulin, Laura M, Cooper, Christopher B, Han, MeiLan K, Huang, Yvonne J, Labaki, Wassim W, Curtis, Jeffrey L, Boucher, Richard C, Study, Subpopulations and Intermediate Outcome Measures in COPD, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Christenson, Stephanie A, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Hansel, Nadia N, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kanner, Richard E, Kleerup, Eric C, Krishnan, Jerry A, LaVange, Lisa M, Lazarus, Stephen C, Martinez, Fernando J, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paine, Robert, Paulin, Laura, Peters, Stephen P, Pirozzi, Cheryl, Putcha, Nirupama, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Lung ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Respiratory ,Good Health and Well Being ,Biomarkers ,Humans ,Hypoxanthines ,N-Acetylneuraminic Acid ,Pulmonary Disease ,Chronic Obstructive ,Sputum ,adenosine ,glutathione ,inflammation ,metabolomics ,methionine salvage ,mucus ,Subpopulations and Intermediate Outcome Measures in COPD Study ,Clinical Sciences ,Respiratory System - Abstract
BackgroundImproved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets.Research questionWhich physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations?Study design and methodsWe applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations.ResultsSputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations.InterpretationBiomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations.Trial registryClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov.
- Published
- 2022
12. Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.
- Author
-
Ronish, Bonnie E, Couper, David J, Barjaktarevic, Igor Z, Cooper, Christopher B, Kanner, Richard E, Pirozzi, Cheryl S, Kim, Victor, Wells, James M, Han, MeiLan K, Woodruff, Prescott G, Ortega, Victor E, Peters, Stephen P, Hoffman, Eric A, Buhr, Russell G, Dolezal, Brett A, Tashkin, Donald P, Liou, Theodore G, Bateman, Lori A, Schroeder, Joyce D, Martinez, Fernando J, Barr, R Graham, Hansel, Nadia N, Comellas, Alejandro P, Rennard, Stephen I, Arjomandi, Mehrdad, and Paine Iii, Robert
- Subjects
Epidemiology ,Biomedical and Clinical Sciences ,Health Sciences ,Clinical Research ,Lung ,Emphysema ,Chronic Obstructive Pulmonary Disease ,Respiratory ,spirometry ,pulmonary physiology ,emphysema ,FEF25-75% ,mid-flow rate ,functional small airways disease - Abstract
BackgroundForced expiratory volume in 1 second (FEV1) is central to the diagnosis of chronic obstructive pulmonary disease (COPD) but is imprecise in classifying disease burden. We examined the potential of the maximal mid-expiratory flow rate (forced expiratory flow rate between 25% and 75% [FEF25%-75%]) as an additional tool for characterizing pathophysiology in COPD.ObjectiveTo determine whether FEF25%-75% helps predict clinical and radiographic abnormalities in COPD.Study design and methodsThe SubPopulations and InteRediate Outcome Measures In COPD Study (SPIROMICS) enrolled a prospective cohort of 2978 nonsmokers and ever-smokers, with and without COPD, to identify phenotypes and intermediate markers of disease progression. We used baseline data from 2771 ever-smokers from the SPIROMICS cohort to identify associations between percent predicted FEF25%-75% (%predFEF25%-75%) and both clinical markers and computed tomography (CT) findings of smoking-related lung disease.ResultsLower %predFEF25-75% was associated with more severe disease, manifested radiographically by increased functional small airways disease, emphysema (most notably with homogeneous distribution), CT-measured residual volume, total lung capacity (TLC), and airway wall thickness, and clinically by increased symptoms, decreased 6-minute walk distance, and increased bronchodilator responsiveness (BDR). A lower %predFEF25-75% remained significantly associated with increased emphysema, functional small airways disease, TLC, and BDR after adjustment for FEV1 or forced vital capacity (FVC).InterpretationThe %predFEF25-75% provides additional information about disease manifestation beyond FEV1. These associations may reflect loss of elastic recoil and air trapping from emphysema and intrinsic small airways disease. Thus, %predFEF25-75% helps link the anatomic pathology and deranged physiology of COPD.
- Published
- 2022
13. Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD Analysis of the SPIROMICS Cohort
- Author
-
Yee, Nathan, Markovic, Daniela, Buhr, Russell G, Fortis, Spyridon, Arjomandi, Mehrdad, Couper, David, Anderson, Wayne H, Paine, Robert, Woodruff, Prescott G, Han, Meilan K, Martinez, Fernando J, Barr, R Graham, Wells, James M, Ortega, Victor E, Hoffman, Eric A, Kim, Victor, Drummond, M Bradley, Bowler, Russell P, Curtis, Jeffrey L, Cooper, Christopher B, Tashkin, Donald P, and Barjaktarevic, Igor Z
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Lung ,Respiratory ,Bronchodilator Agents ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Respiration Disorders ,Smokers ,Spirometry ,Vital Capacity ,COPD ,early airflow obstruction ,small airways disease ,spirometry ,FEV3 ,FEV6 ,FEV3/FEV6 ,FEV(3) ,FEV(3)/FEV(6) ,FEV(6) ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundSmall airways are known to be affected early in the course of COPD; however, traditional spirometric indices may not accurately identify small airways disease.Research questionCan forced expiratory volume in 3 s/forced expiratory volume in 6 s (FEV3/FEV6) identify early airflow abnormalities and predict future clinically important respiratory-related outcomes, including development of COPD?Study design and methodsThe study included 832 current and former smokers with post-bronchodilator FEV1/FVC ≥ 0.7 from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Participants were classified as having a reduced pre-bronchodilator FEV3/FEV6 based on lower limit of normal (LLN) values. Repeatability analysis was performed for FEV3 and FEV6. Regression modeling was used to evaluate the relationship between baseline FEV3/FEV6 and outcome measures, including functional small airways disease, on thoracic imaging and respiratory exacerbations. Interval-censored analysis was used to assess progression to COPD.ResultsFEV3/FEV6 less than the LLN at baseline, defined as reduced compared with FEV3/FEV6 at or above the LLN, was associated with lower FEV1, poorer health status (St. George's Respiratory Questionnaire score), more emphysema, and more functional small airways disease on quantitative imaging. FEV3 and FEV6 showed excellent agreement between repeat measurements. A reduced FEV3/FEV6 was associated with increased odds of a severe respiratory exacerbation within the first year of follow-up and decreased time to first exacerbation. A low FEV3/FEV6 was also associated with development of COPD according to spirometry results (post-bronchodilator FEV1/FVC < 0.7) during study follow-up.InterpretationFEV3/FEV6 is a routinely available and repeatable spirometric index that can be useful in the evaluation of early airflow obstruction in current and former smokers without COPD. A reduced FEV3/FEV6 can identify those at risk for future development of COPD and respiratory exacerbations.Clinical trial registrationClinicalTrials.gov; No.: NCT01969344; URL: www.Clinicaltrialsgov: ClinicalTrials.gov.
- Published
- 2022
14. Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.
- Author
-
Krishnan, Jamuna K, Ancy, Kayley M, Oromendia, Clara, Hoffman, Katherine L, Easthausen, Imaani, Leidy, Nancy K, Han, MeiLan K, Bowler, Russell P, Christenson, Stephanie A, Couper, David J, Criner, Gerard J, Curtis, Jeffrey L, Dransfield, Mark T, Hansel, Nadia N, Iyer, Anand S, Paine Iii, Robert, Peters, Stephen P, Wedzicha, Jadwiga A, Woodruff, Prescott G, Ballman, Karla V, Martinez, Fernando J, and SPIROMICS Investigators
- Subjects
SPIROMICS Investigators ,EXACT ,chronic obstructive pulmonary disease ,exacerbations ,patient-reported outcomes ,symptom variation ,Chronic Obstructive Pulmonary Disease ,Lung ,Clinical Research ,Respiratory - Abstract
RationaleIt has been suggested that patients with chronic obstructive pulmonary disease (COPD) experience considerable daily respiratory symptom fluctuation. A standardized measure is needed to quantify and understand the implications of day-to-day symptom variability.ObjectivesTo compare standard deviation with other statistical measures of symptom variability and identify characteristics of individuals with higher symptom variability.MethodsIndividuals in the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Exacerbations sub-study completed an Evaluating Respiratory Symptoms in COPD (E-RS) daily questionnaire. We calculated within-subject standard deviation (WS-SD) for each patient at week 0 and correlated this with measurements obtained 4 weeks later using Pearson's r and Bland Altman plots. Median WS-SD value dichotomized participants into higher versus lower variability groups. Association between WS-SD and exacerbation risk during 4 follow-up weeks was explored.Measurements and main resultsDiary completion rates were sufficient in 140 (68%) of 205 sub-study participants. Reproducibility (r) of the WS-SD metric from baseline to week 4 was 0.32. Higher variability participants had higher St George's Respiratory Questionnaire (SGRQ) scores (47.3 ± 20.3 versus 39.6 ± 21.5, p=.04) than lower variability participants. Exploratory analyses found no relationship between symptom variability and health care resource utilization-defined exacerbations.ConclusionsWS-SD of the E-RS can be used as a measure of symptom variability in studies of patients with COPD. Patients with higher variability have worse health-related quality of life. WS-SD should be further validated as a measure to understand the implications of symptom variability.
- Published
- 2022
15. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study
- Author
-
Kim, John S., Murray, Susan, Yow, Eric, Anstrom, Kevin J., Kim, Hyun J., Flaherty, Kevin R., Martinez, Fernando J., and Noth, Imre
- Published
- 2024
- Full Text
- View/download PDF
16. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
- Author
-
Rahaghi, Franck F., Hsu, Vivien M., Kaner, Robert J., Mayes, Maureen D., Rosas, Ivan O., Saggar, Rajan, Steen, Virginia D., Strek, Mary E., Bernstein, Elana J., Bhatt, Nitin, Castelino, Flavia V., Chung, Lorinda, Domsic, Robyn T., Flaherty, Kevin R., Gupta, Nishant, Kahaleh, Bashar, Martinez, Fernando J., Morrow, Lee E., Moua, Teng, Patel, Nina, Shlobin, Oksana A., Southern, Brian D., Volkmann, Elizabeth R., and Khanna, Dinesh
- Published
- 2023
- Full Text
- View/download PDF
17. A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD
- Author
-
DiLillo, Katarina M., Norman, Katy C., Freeman, Christine M., Christenson, Stephanie A., Alexis, Neil E., Anderson, Wayne H., Barjaktarevic, Igor Z., Barr, R. Graham, Comellas, Alejandro P., Bleecker, Eugene R., Boucher, Richard C., Couper, David J., Criner, Gerard J., Doerschuk, Claire M., Wells, J. Michael, Han, MeiLan K., Hoffman, Eric A., Hansel, Nadia N., Hastie, Annette T., Kaner, Robert J., Krishnan, Jerry A., Labaki, Wassim W., Martinez, Fernando J., Meyers, Deborah A., O’Neal, Wanda K., Ortega, Victor E., Paine, III, Robert, Peters, Stephen P., Woodruff, Prescott G., Cooper, Christopher B., Bowler, Russell P., Curtis, Jeffrey L., and Arnold, Kelly B.
- Published
- 2023
- Full Text
- View/download PDF
18. Comparative Impact of Depressive Symptoms and FEV1% on Chronic Obstructive Pulmonary Disease.
- Author
-
O’Toole, Jacqueline, Woo, Han, Putcha, Nirupama, Cooper, Christopher B, Woodruff, Prescott, Kanner, Richard E, Paine, Robert, Bowler, Russell P, Comellas, Alejandro, Hoth, Karin F, Krishnan, Jerry A, Han, Meilan, Dransfield, Mark, Iyer, Anand S, Couper, David, Peters, Stephen P, Criner, Gerard, Kim, Victor, Barr, R Graham, Martinez, Fernando J, Hansel, Nadia N, Eakin, Michelle N, Alexis, Neil E, Anderson, Wayne H, Arjomandi, Mehrdad, Barjaktarevic, Igor, Bateman, Lori A, Bhatt, Surya P, Bleecker, Eugene R, Boucher, Richard C, Christenson, Stephanie A, Comellas, Alejandro P, Couper, David J, Criner, Gerard J, Crystal, Ronald G, Curtis, Jeffrey L, Doerschuk, Claire M, Dransfield, Mark T, Drummond, Brad, Freeman, Christine M, Galban, Craig, Han, MeiLan K, Hastie, Annette T, Hoffman, Eric A, Huang, Yvonne, Kaner, Robert J, Kleerup, Eric C, LaVange, Lisa M, Lazarus, Stephen C, Meyers, Deborah A, Moore, Wendy C, Newell, John D, Paulin, Laura, Pirozzi, Cheryl, Oelsner, Elizabeth C, O’Neal, Wanda K, Ortega, Victor E, Raman, Sanjeev, Rennard, Stephen I, Tashkin, Donald P, Wells, J Michael, Wise, Robert A, and Woodruff, Prescott G
- Subjects
Clinical Research ,Behavioral and Social Science ,Depression ,Chronic Obstructive Pulmonary Disease ,Mental Health ,Lung ,Respiratory ,Good Health and Well Being ,Female ,Forced Expiratory Volume ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Respiratory Function Tests ,Smoking ,Surveys and Questionnaires ,depression ,COPD ,patient reported outcome measures ,SPIROMICS Investigators - Abstract
Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have a high prevalence of depression, which is associated with increased COPD hospitalizations and readmissions. Objectives: Examine the impact of depressive symptoms compared with FEV1% on COPD morbidity. Methods: Using longitudinal data from individuals with COPD in the Subpopulations and Intermediate Outcome Measures in COPD Study, longitudinal growth analysis was performed to assess COPD morbidity by assessing differences in baseline 6-minute walk distance and patient reported outcomes (PROs) and their rate of change over time explained by depressive symptoms or lung function, as measured by Hospital Anxiety and Depression Scale or FEV1% respectively. PROs consisted of in-person completion of St. George's Respiratory Questionnaire, COPD Assessment Test, Functional Assessment of Chronic Illness Therapy Fatigue, and Modified Medical Research Council Dyspnea Scale measures. Results: Of the individuals analyzed (n = 1,830), 43% were female, 81% Caucasian with mean ± SD age of 65.1 ± 8.1, and 52.7 ± 27.5 pack-years smoking. Mean ± SD FEV1% was 60.9 ± 23.0% and 20% had clinically significant depressive symptoms. Adjusted models showed higher Hospital Anxiety and Depression Scale scores and lower FEV1% each were associated with worse PROs at baseline (P ⩽ 0.001). Depression accounted for more baseline variance in St. George's Respiratory Questionnaire, COPD Assessment Test, and Functional Assessment of Chronic Illness Therapy Fatigue than FEV1%, explaining 30-67% of heterogeneity. FEV1% accounted for more baseline variance in Modified Medical Research Council Dyspnea Scale and 6-minute walk distance than depression, explaining 16-32% of heterogeneity. Depressive symptoms accounted for 3-17% variance in change over time in PROs. In contrast, FEV1% accounted for 1-4% variance over time in PROs. Conclusions: Depression is more strongly associated with many PROs at baseline and their change over time compared with FEV1%. Recognizing and incorporating the impact of depressive symptoms into individualized care may improve COPD outcomes.
- Published
- 2022
19. Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease.
- Author
-
Ghosh, Auyon J, Hobbs, Brian D, Moll, Matthew, Saferali, Aabida, Boueiz, Adel, Yun, Jeong H, Sciurba, Frank, Barwick, Lucas, Limper, Andrew H, Flaherty, Kevin, Criner, Gerard, Brown, Kevin K, Wise, Robert, Martinez, Fernando J, Lomas, David, Castaldi, Peter J, Carey, Vincent J, DeMeo, Dawn L, Cho, Michael H, Silverman, Edwin K, Hersh, Craig P, Crapo, James D, Make, Barry J, Regan, Elizabeth A, Beaty, Terri H, El-Boueiz, Adel, Foreman, Marilyn G, Hayden, Lystra P, Hetmanski, Jacqueline, Hokanson, John E, Kim, Wonji, Laird, Nan, Lange, Christoph, Lutz, Sharon M, McDonald, Merry-Lynn, Prokopenko, Dmitry, Morrow, Jarrett, Qiao, Dandi, Sakornsakolpat, Phuwanat, Wan, Emily S, Centeno, Juan Pablo, Charbonnier, Jean-Paul, Coxson, Harvey O, Galban, Craig J, Han, MeiLan K, Hoffman, Eric A, Humphries, Stephen, Jacobson, Francine L, Judy, Philip F, Kazerooni, Ella A, Kluiber, Alex, Lynch, David A, Nardelli, Pietro, Newell, John D, Notary, Aleena, Oh, Andrea, Ross, James C, Estepar, Raul San Jose, Schroeder, Joyce, Sieren, Jered, Stoel, Berend C, Tschirren, Juerg, Van Beek, Edwin, van Ginneken, Bram, van Rikxoort, Eva, Sanchez-Ferrero, Gonzalo Vegas, Veitel, Lucas, Washko, George R, Wilson, Carla G, Jensen, Robert, Everett, Douglas, Crooks, Jim, Pratte, Katherine, Strand, Matt, Austin, Erin, Kinney, Gregory, Young, Kendra A, Bhatt, Surya P, Bon, Jessica, Diaz, Alejandro A, Make, Barry, Murray, Susan, Regan, Elizabeth, Soler, Xavier, Bowler, Russell P, Kechris, Katerina, Banaei-Kashani, Farnoush, Curtis, Jeffrey L, Pernicano, Perry G, and Hanania, Nicola
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Chronic Obstructive Pulmonary Disease ,Lung ,Emphysema ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Respiratory ,Adult ,Aged ,Aged ,80 and over ,Case-Control Studies ,Female ,Genetic Markers ,Genotype ,Heterozygote ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Phenotype ,Pulmonary Disease ,Chronic Obstructive ,Respiratory Function Tests ,Survival Analysis ,Whole Genome Sequencing ,alpha 1-Antitrypsin ,COPDGene Investigators ,RNA sequencing ,alpha-1 antitrypsin ,chronic obstructive pulmonary disease ,meta-analysis ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: Multiple studies have demonstrated an increased risk of chronic obstructive pulmonary disease (COPD) in heterozygous carriers of the AAT (alpha-1 antitrypsin) Z allele. However, it is not known if MZ subjects with COPD are phenotypically different from noncarriers (MM genotype) with COPD. Objectives: To assess if MZ subjects with COPD have different clinical features compared with MM subjects with COPD. Methods: Genotypes of SERPINA1 were ascertained by using whole-genome sequencing data in three independent studies. We compared outcomes between MM subjects with COPD and MZ subjects with COPD in each study and combined the results in a meta-analysis. We performed longitudinal and survival analyses to compare outcomes in MM and MZ subjects with COPD over time. Measurements and Main Results: We included 290 MZ subjects with COPD and 6,184 MM subjects with COPD across the three studies. MZ subjects had a lower FEV1% predicted and greater quantitative emphysema on chest computed tomography scans compared with MM subjects. In a meta-analysis, the FEV1 was 3.9% lower (95% confidence interval [CI], -6.55% to -1.26%) and emphysema (the percentage of lung attenuation areas
- Published
- 2022
20. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
- Author
-
Podolanczuk, Anna J, Kim, John S, Cooper, Christopher B, Lasky, Joseph A, Murray, Susan, Oldham, Justin M, Raghu, Ganesh, Flaherty, Kevin R, Spino, Cathie, Noth, Imre, and Martinez, Fernando J
- Subjects
Rare Diseases ,Clinical Trials and Supportive Activities ,Genetics ,Lung ,Complementary and Integrative Health ,Clinical Research ,Autoimmune Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Good Health and Well Being ,Humans ,Acetylcysteine ,Double-Blind Method ,Genotype ,Idiopathic Pulmonary Fibrosis ,Treatment Outcome ,Vital Capacity ,Randomized Controlled Trials as Topic ,Multicenter Studies as Topic ,Clinical Trials ,Phase III as Topic ,IPF ,Clinical trial ,Protocol ,N-acetylcysteine ,PRECISIONS Study Team ,Cardiorespiratory Medicine and Haematology ,Respiratory System - Abstract
BackgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. N-acetylcysteine (NAC) is a well-tolerated, inexpensive treatment with antioxidant and anti-fibrotic properties. The National Heart, Lung, and Blood Institute (NHLBI)-sponsored PANTHER (Prednisone Azathioprine and NAC therapy in IPF) trial confirmed the harmful effects of immunosuppression in IPF, and did not show a benefit to treatment with NAC. However, a post hoc analysis revealed a potential beneficial effect of NAC in a subgroup of individuals carrying a specific genetic variant, TOLLIP rs3750920 TT genotype, present in about 25% of patients with IPF. Here, we present the design and rationale for the Phase III, multi-center, randomized, double-blind, placebo-controlled Prospective Treatment Efficacy in IPF Using Genotype for NAC Selection (PRECISIONS) clinical trial.MethodsThe PRECISIONS trial will randomize 200 patients with IPF and the TOLLIP rs3750920 TT genotype 1:1 to oral N-acetylcysteine (600 mg tablets taken three times a day) or placebo for a 24-month duration. The primary endpoint is the composite of time to 10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or death from any cause. Secondary endpoints include change in patient-reported outcome scores and proportion of participants with treatment-emergent adverse events. Biospecimens, including blood, buccal, and fecal will be collected longitudinally for future research purposes. Study participants will be offered enrollment in a home spirometry substudy, which explores time to 10% relative FVC decline measured at home, and its comparison with study visit FVC.DiscussionThe sentinel observation of a potential pharmacogenetic interaction between NAC and TOLLIP polymorphism highlights the urgent, unmet need for better, molecularly focused, and precise therapeutic strategies in IPF. The PRECISIONS clinical trial is the first study to use molecularly-focused techniques to identify patients with IPF most likely to benefit from treatment. PRECISIONS has the potential to shift the paradigm in how trials in this condition are designed and executed, and is the first step toward personalized medicine for patients with IPF. Trial Registration ClinicalTrials.gov identifier: NCT04300920. Registered March 9, 2020. https://clinicaltrials.gov/ct2/show/NCT04300920.
- Published
- 2022
21. Interventions to Improve Quality of Life and Knowledge in Hypersensitivity Pneumonitis: A Survey of Clinician Practices and Perspectives
- Author
-
Aronson, Kerri I., Holbrook, Nancy, Edgar, Armani, Anderson, Michaela R., Krishnan, Jamuna K., Kaner, Robert J., Podolanczuk, Anna J., Martinez, Fernando J., Tobin, Johnathan N., and Safford, Monika M.
- Published
- 2024
- Full Text
- View/download PDF
22. Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease
- Author
-
Hernández Cordero, Ana I, Yang, Chen Xi, Li, Xuan, Milne, Stephen, Chen, Virginia, Hollander, Zsuzsanna, Ng, Raymond, Criner, Gerard J, Woodruff, Prescott G, Lazarus, Stephen C, Connett, John E, Han, MeiLan K, Martinez, Fernando J, Reed, Robert M, Man, SF Paul, Leung, Janice M, and Sin, Don D
- Subjects
Chronic Obstructive Pulmonary Disease ,Lung ,Genetics ,Clinical Research ,Prevention ,Respiratory ,Adult ,Aged ,Anti-Bacterial Agents ,Azithromycin ,Biomarkers ,DNA Methylation ,Disease Progression ,Female ,Follow-Up Studies ,Hospitalization ,Humans ,Incidence ,Male ,Middle Aged ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Retrospective Studies ,Surveys and Questionnaires ,Telomere ,Time Factors ,United States ,COPD ,Telomeres ,AECOPD ,Epigenetics ,DNA methylation ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Respiratory System - Abstract
BackgroundChronic obstructive pulmonary disease (COPD) is an age-related condition that has been associated with early telomere attrition; the clinical implications of telomere shortening in COPD are not well known. In this study we aimed to determine the relationship of the epigenetic regulation of telomeric length in peripheral blood with the risk of exacerbations and hospitalization in patients with COPD.MethodsBlood DNA methylation profiles were obtained from 292 patients with COPD enrolled in the placebo arm of the Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated with Chronic Obstructive Pulmonary Disease (MACRO) Study and who were followed for 1-year. We calculated telomere length based on DNA methylation markers (DNAmTL) and related this biomarker to the risk of exacerbation and hospitalization and health status (St. George Respiratory Questionnaire [SGRQ]) score over time using a Cox proportional hazards model. We also used linear models to investigate the associations of DNAmTL with the rates of exacerbation and hospitalization (adjusted for chronological age, lung function, race, sex, smoking, body mass index and cell composition).ResultsParticipants with short DNAmTL demonstrated increased risk of exacerbation (P = 0.02) and hospitalization (P = 0.03) compared to those with longer DNAmTL. DNAmTL age acceleration was associated with higher rates of exacerbation (P = 1.35 × 10-04) and hospitalization (P = 5.21 × 10-03) and poor health status (lower SGRQ scores) independent of chronological age (P = 0.03).ConclusionTelomeric age based on blood DNA methylation is associated with COPD exacerbation and hospitalization and thus a promising biomarker for poor outcomes in COPD.
- Published
- 2021
23. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium
- Author
-
Kasela, Silva, Ortega, Victor E, Martorella, Molly, Garudadri, Suresh, Nguyen, Jenna, Ampleford, Elizabeth, Pasanen, Anu, Nerella, Srilaxmi, Buschur, Kristina L, Barjaktarevic, Igor Z, Barr, R Graham, Bleecker, Eugene R, Bowler, Russell P, Comellas, Alejandro P, Cooper, Christopher B, Couper, David J, Criner, Gerard J, Curtis, Jeffrey L, Han, MeiLan K, Hansel, Nadia N, Hoffman, Eric A, Kaner, Robert J, Krishnan, Jerry A, Martinez, Fernando J, McDonald, Merry-Lynn N, Meyers, Deborah A, Paine, Robert, Peters, Stephen P, Castro, Mario, Denlinger, Loren C, Erzurum, Serpil C, Fahy, John V, Israel, Elliot, Jarjour, Nizar N, Levy, Bruce D, Li, Xingnan, Moore, Wendy C, Wenzel, Sally E, Zein, Joe, Langelier, Charles, Woodruff, Prescott G, Lappalainen, Tuuli, and Christenson, Stephanie A
- Subjects
Biological Sciences ,Genetics ,Lung ,Clinical Research ,Infectious Diseases ,Prevention ,Emerging Infectious Diseases ,Human Genome ,2.2 Factors relating to the physical environment ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Respiratory ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Angiotensin-Converting Enzyme 2 ,Asthma ,Bronchi ,COVID-19 ,Cardiovascular Diseases ,Gene Expression ,Genetic Variation ,Humans ,Middle Aged ,Obesity ,Pulmonary Disease ,Chronic Obstructive ,Quantitative Trait Loci ,Respiratory Mucosa ,Risk Factors ,SARS-CoV-2 ,Smoking ,ACE2 ,eQTL ,Bronchial epithelium ,NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study ,NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium ,Clinical Sciences - Abstract
BackgroundThe large airway epithelial barrier provides one of the first lines of defense against respiratory viruses, including SARS-CoV-2 that causes COVID-19. Substantial inter-individual variability in individual disease courses is hypothesized to be partially mediated by the differential regulation of the genes that interact with the SARS-CoV-2 virus or are involved in the subsequent host response. Here, we comprehensively investigated non-genetic and genetic factors influencing COVID-19-relevant bronchial epithelial gene expression.MethodsWe analyzed RNA-sequencing data from bronchial epithelial brushings obtained from uninfected individuals. We related ACE2 gene expression to host and environmental factors in the SPIROMICS cohort of smokers with and without chronic obstructive pulmonary disease (COPD) and replicated these associations in two asthma cohorts, SARP and MAST. To identify airway biology beyond ACE2 binding that may contribute to increased susceptibility, we used gene set enrichment analyses to determine if gene expression changes indicative of a suppressed airway immune response observed early in SARS-CoV-2 infection are also observed in association with host factors. To identify host genetic variants affecting COVID-19 susceptibility in SPIROMICS, we performed expression quantitative trait (eQTL) mapping and investigated the phenotypic associations of the eQTL variants.ResultsWe found that ACE2 expression was higher in relation to active smoking, obesity, and hypertension that are known risk factors of COVID-19 severity, while an association with interferon-related inflammation was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, are similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19, some of which had pheWAS evidence for their potential role in respiratory infections.ConclusionsThese data provide evidence that clinically relevant variation in the expression of COVID-19-related genes is associated with host factors, environmental exposures, and likely host genetic variation.
- Published
- 2021
24. Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.
- Author
-
Ejike, Chinedu O, Woo, Han, Galiatsatos, Panagis, Paulin, Laura M, Krishnan, Jerry A, Cooper, Christopher B, Couper, David J, Kanner, Richard E, Bowler, Russell P, Hoffman, Eric A, Comellas, Alejandro P, Criner, Gerard J, Barr, R Graham, Martinez, Fernando J, Han, MeiLan K, Martinez, Carlos H, Ortega, Victor E, Parekh, Trisha M, Christenson, Stephanie A, Thakur, Neeta, Baugh, Aaron, Belz, Daniel C, Raju, Sarath, Gassett, Amanda J, Kaufman, Joel D, Putcha, Nirupama, and Hansel, Nadia N
- Subjects
Lung ,Clinical Research ,Behavioral and Social Science ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Adult ,Black or African American ,Aged ,Aged ,80 and over ,Female ,Health Status Disparities ,Healthcare Disparities ,Humans ,Male ,Middle Aged ,Outcome Assessment ,Health Care ,Pulmonary Disease ,Chronic Obstructive ,Race Factors ,Smoking ,Social Class ,Socioeconomic Factors ,Surveys and Questionnaires ,White People ,COPD ,racial disparities ,socioeconomic status ,neighborhood disadvantage ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: Black adults have worse health outcomes compared with white adults in certain chronic diseases, including chronic obstructive pulmonary disease (COPD).Objectives: To determine to what degree disadvantage by individual and neighborhood socioeconomic status (SES) may contribute to racial disparities in COPD outcomes.Methods: Individual and neighborhood-scale sociodemographic characteristics were determined in 2,649 current or former adult smokers with and without COPD at recruitment into SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study). We assessed whether racial differences in symptom, functional, and imaging outcomes (St. George's Respiratory Questionnaire, COPD Assessment Test score, modified Medical Research Council dyspnea scale, 6-minute-walk test distance, and computed tomography [CT] scan metrics) and severe exacerbation risk were explained by individual or neighborhood SES. Using generalized linear mixed model regression, we compared respiratory outcomes by race, adjusting for confounders and individual-level and neighborhood-level descriptors of SES both separately and sequentially.Measurements and Main Results: After adjusting for COPD risk factors, Black participants had significantly worse respiratory symptoms and quality of life (modified Medical Research Council scale, COPD Assessment Test, and St. George's Respiratory Questionnaire), higher risk of severe exacerbations and higher percentage of emphysema, thicker airways (internal perimeter of 10 mm), and more air trapping on CT metrics compared with white participants. In addition, the association between Black race and respiratory outcomes was attenuated but remained statistically significant after adjusting for individual-level SES, which explained up to 12-35% of racial disparities. Further adjustment showed that neighborhood-level SES explained another 26-54% of the racial disparities in respiratory outcomes. Even after accounting for both individual and neighborhood SES factors, Black individuals continued to have increased severe exacerbation risk and persistently worse CT outcomes (emphysema, air trapping, and airway wall thickness).Conclusions: Disadvantages by individual- and neighborhood-level SES each partly explain disparities in respiratory outcomes between Black individuals and white individuals. Strategies to narrow the gap in SES disadvantages may help to reduce race-related health disparities in COPD; however, further work is needed to identify additional risk factors contributing to persistent disparities.
- Published
- 2021
25. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.
- Author
-
Dunican, Eleanor M, Elicker, Brett M, Henry, Travis, Gierada, David S, Schiebler, Mark L, Anderson, Wayne, Barjaktarevic, Igor, Barr, R Graham, Bleecker, Eugene R, Boucher, Richard C, Bowler, Russell, Christenson, Stephanie A, Comellas, Alejandro, Cooper, Christopher B, Couper, David, Criner, Gerard J, Dransfield, Mark, Doerschuk, Claire M, Drummond, M Bradley, Hansel, Nadia N, Han, MeiLan K, Hastie, Annette T, Hoffman, Eric A, Krishnan, Jerry A, Lazarus, Stephen C, Martinez, Fernando J, McCulloch, Charles E, O'Neal, Wanda K, Ortega, Victor E, Paine, Robert, Peters, Stephen, Schroeder, Joyce D, Woodruff, Prescott G, and Fahy, John V
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Emphysema ,Clinical Trials and Supportive Activities ,Lung ,Respiratory ,Aged ,Female ,Forced Expiratory Volume ,Healthy Volunteers ,Humans ,Hypoxia ,Male ,Middle Aged ,Mucus ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Respiratory Function Tests ,Smokers ,Smoking ,Vital Capacity ,COPD ,computed tomography ,FEV1 ,mucus plugs ,emphysema ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: The relative roles of mucus plugs and emphysema in mechanisms of airflow limitation and hypoxemia in smokers with chronic obstructive pulmonary disease (COPD) are uncertain.Objectives: To relate image-based measures of mucus plugs and emphysema to measures of airflow obstruction and oxygenation in patients with COPD.Methods: We analyzed computed tomographic (CT) lung images and lung function in participants in the Subpopulations and Intermediate Outcome Measures in COPD Study. Radiologists scored mucus plugs on CT lung images, and imaging software automatically quantified emphysema percentage. Unadjusted and adjusted relationships between mucus plug score, emphysema percentage, and lung function were determined using regression.Measurements and Main Results: Among 400 smokers, 229 (57%) had mucus plugs and 207 (52%) had emphysema, and subgroups could be identified with mucus-dominant and emphysema-dominant disease. Only 33% of smokers with high mucus plug scores had mucus symptoms. Mucus plug score and emphysema percentage were independently associated with lower values for FEV1 and peripheral oxygen saturation (P
- Published
- 2021
26. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD
- Author
-
Pirie, Elaine, Oh, Chang-Ki, Zhang, Xu, Han, Xuemei, Cieplak, Piotr, Scott, Henry R, Deal, Amanda K, Ghatak, Swagata, Martinez, Fernando J, Yeo, Gene W, Yates, John R, Nakamura, Tomohiro, and Lipton, Stuart A
- Subjects
ALS ,Stem Cell Research ,Neurosciences ,Dementia ,Acquired Cognitive Impairment ,Frontotemporal Dementia (FTD) ,Neurodegenerative ,Rare Diseases ,Brain Disorders ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Amyotrophic Lateral Sclerosis ,Brain ,Cysteine ,DNA-Binding Proteins ,Frontotemporal Dementia ,Humans ,Induced Pluripotent Stem Cells ,Motor Neurons ,Nitric Oxide ,Protein Aggregation ,Pathological ,RNA Processing ,Post-Transcriptional ,Reactive Nitrogen Species ,S-Nitrosothiols ,Stress ,Physiological ,TDP-43 proteinopathy ,S-nitrosylation ,aggregation ,spread - Abstract
Rare genetic mutations result in aggregation and spreading of cognate proteins in neurodegenerative disorders; however, in the absence of mutation (i.e., in the vast majority of "sporadic" cases), mechanisms for protein misfolding/aggregation remain largely unknown. Here, we show environmentally induced nitrosative stress triggers protein aggregation and cell-to-cell spread. In patient brains with amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD), aggregation of the RNA-binding protein TDP-43 constitutes a major component of aberrant cytoplasmic inclusions. We identify a pathological signaling cascade whereby reactive nitrogen species cause S-nitrosylation of TDP-43 (forming SNO-TDP-43) to facilitate disulfide linkage and consequent TDP-43 aggregation. Similar pathological SNO-TDP-43 levels occur in postmortem human FTD/ALS brains and in cell-based models, including human-induced pluripotent stem cell (hiPSC)-derived neurons. Aggregated TDP-43 triggers additional nitrosative stress, representing positive feed forward leading to further SNO-TDP-43 formation and disulfide-linked oligomerization/aggregation. Critically, we show that these redox reactions facilitate cell spreading in vivo and interfere with the TDP-43 RNA-binding activity, affecting SNMT1 and phospho-(p)CREB levels, thus contributing to neuronal damage in ALS/FTD disorders.
- Published
- 2021
27. Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
- Author
-
Zou, Chunrui, Li, Frank, Choi, Jiwoong, Haghighi, Babak, Choi, Sanghun, Rajaraman, Prathish K, Comellas, Alejandro P, Newell, John D, Lee, Chang Hyun, Barr, R Graham, Bleecker, Eugene, Cooper, Christopher B, Couper, David, Han, Meilan, Hansel, Nadia N, Kanner, Richard E, Kazerooni, Ella A, Kleerup, Eric C, Martinez, Fernando J, O’Neal, Wanda, Paine, Robert, Rennard, Stephen I, Smith, Benjamin M, Woodruff, Prescott G, Hoffman, Eirc A, and Lin, Ching-Long
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Lung ,Biomedical Imaging ,Respiratory ,Cross-Sectional Studies ,Humans ,Outcome Assessment ,Health Care ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Smokers ,computed tomography ,emphysema ,functional small airway disease ,longitudinal clustering ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
PurposeQuantitative computed tomography (qCT) imaging-based cluster analysis identified clinically meaningful COPD former-smoker subgroups (clusters) based on cross-sectional data. We aimed to identify progression clusters for former smokers using longitudinal data.Patients and methodsWe selected 472 former smokers from SPIROMICS with a baseline visit and a one-year follow-up visit. A total of 150 qCT imaging-based variables, comprising 75 variables at baseline and their corresponding progression rates, were derived from the respective inspiration and expiration scans of the two visits. The COPD progression clusters identified were then associated with subject demography, clinical variables and biomarkers.ResultsCOPD severities at baseline increased with increasing cluster number. Cluster 1 patients were an obese subgroup with rapid progression of functional small airway disease percentage (fSAD%) and emphysema percentage (Emph%). Cluster 2 exhibited a decrease of fSAD% and Emph%, an increase of tissue fraction at total lung capacity and airway narrowing over one year. Cluster 3 showed rapid expansion of Emph% and an attenuation of fSAD%. Cluster 4 demonstrated severe emphysema and fSAD and significant structural alterations at baseline with rapid progression of fSAD% over one year. Subjects with different progression patterns in the same cross-sectional cluster were identified by longitudinal clustering.ConclusionqCT imaging-based metrics at two visits for former smokers allow for the derivation of four statistically stable clusters associated with unique progression patterns and clinical characteristics. Use of baseline variables and their progression rates enables identification of longitudinal clusters, resulting in a refinement of cross-sectional clusters.
- Published
- 2021
28. Clinical Phenotypes of Atopy and Asthma in COPD A Meta-analysis of SPIROMICS and COPDGene
- Author
-
Putcha, Nirupama, Fawzy, Ashraf, Matsui, Elizabeth C, Liu, Mark C, Bowler, Russ P, Woodruff, Prescott G, O'Neal, Wanda K, Comellas, Alejandro P, Han, MeiLan K, Dransfield, Mark T, Wells, J Michael, Lugogo, Njira, Gao, Li, Talbot, C Conover, Hoffman, Eric A, Cooper, Christopher B, Paulin, Laura M, Kanner, Richard E, Criner, Gerard, Ortega, Victor E, Barr, R Graham, Krishnan, Jerry A, Martinez, Fernando J, Drummond, M Bradley, Wise, Robert A, Diette, Gregory B, Hersh, Craig P, and Hansel, Nadia N
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Tobacco Smoke and Health ,Lung ,Clinical Research ,Tobacco ,Asthma ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome ,Biological Variation ,Population ,Disease Management ,Female ,Humans ,Hypersensitivity ,Immediate ,Immunoglobulin E ,Male ,Middle Aged ,Molecular Epidemiology ,Prevalence ,Pulmonary Disease ,Chronic Obstructive ,Risk Factors ,Smoking ,Status Asthmaticus ,asthma COPD overlap ,atopy ,COPD ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundLittle is known about the concordance of atopy with asthma COPD overlap. Among individuals with COPD, a better understanding of the phenotypes characterized by asthma overlap and atopy is needed to better target therapies.Research questionWhat is the overlap between atopy and asthma status among individuals with COPD, and how are categories defined by the presence of atopy and asthma status associated with clinical and radiologic phenotypes and outcomes in the Genetic Epidemiology of COPD Study (COPDGene) and Subpopulation and Intermediate Outcome Measures in COPD Study (SPIROMICS)?Study design and methodsFour hundred three individuals with COPD from SPIROMICS and 696 individuals from COPDGene with data about specific IgEs to 10 common allergens and mixes (simultaneous assessment of combination of allergens in similar category) were included. Comparison groups were defined by atopic and asthma status (neither, atopy alone, atopic asthma, nonatopic asthma, with atopy defined as any positive specific IgE (≥0.35 KU/L) to any of the 10 allergens or mixes and asthma defined as self-report of doctor-diagnosed current asthma). Multivariable regression analyses (linear, logistic, and zero inflated negative binomial where appropriate) adjusted for age, sex, race, lung function, smoking status, pack-years smoked, and use of inhaled corticosteroids were used to determine characteristics of groups and relationship with outcomes (exacerbations, clinical outcomes, CT metrics) separately in COPDGene and SPIROMICS, and then adjusted results were combined using meta-analysis.ResultsThe prevalence of atopy was 35% and 36% in COPD subjects from SPIROMICS and COPDGene, respectively, and less than 50% overlap was seen between atopic status with asthma in both cohorts. In meta-analysis, individuals with nonatopic asthma had the most impaired symptom scores (effect size for St. George's Respiratory Questionnaire total score, 4.2; 95% CI, 0.4-7.9; effect size for COPD Assessment Test score, 2.8; 95% CI, 0.089-5.4), highest risk for exacerbations (incidence rate ratio, 1.41; 95% CI, 1.05-1.88) compared with the group without atopy or asthma. Those with atopy and atopic asthma were not at increased risk for adverse outcomes.InterpretationAsthma and atopy had incomplete overlap among former and current smokers with COPD in COPDGene and SPIROMICS. Nonatopic asthma was associated with adverse outcomes and exacerbation risk in COPD, whereas groups having atopy alone and atopic asthma had less risk.
- Published
- 2020
29. Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records
- Author
-
Onishchenko, Dmytro, Marlowe, Robert J., Ngufor, Che G., Faust, Louis J., Limper, Andrew H., Hunninghake, Gary M., Martinez, Fernando J., and Chattopadhyay, Ishanu
- Published
- 2022
- Full Text
- View/download PDF
30. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
- Author
-
Agustí, Alvar, Celli, Bartolome R., Criner, Gerard J., Halpin, David, Anzueto, Antonio, Barnes, Peter, Bourbeau, Jean, Han, MeiLan K., Martinez, Fernando J., Montes de Oca, Maria, Mortimer, Kevin, Papi, Alberto, Pavord, Ian, Roche, Nicolas, Salvi, Sundeep, Sin, Don D., Singh, Dave, Stockley, Robert, López Varela, M. Victorina, Wedzicha, Jadwiga A., and Vogelmeier, Claus F.
- Published
- 2023
- Full Text
- View/download PDF
31. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life A Secondary Analysis of the Long-Term Oxygen Treatment Trial
- Author
-
Keller, Thomas, Spece, Laura J, Donovan, Lucas M, Udris, Edmunds, Coggeshall, Scott S, Griffith, Matthew, Bryant, Alexander D, Casaburi, Richard, Cooper, J Allen, Criner, Gerard J, Diaz, Philip T, Fuhlbrigge, Anne L, Gay, Steven E, Kanner, Richard E, Martinez, Fernando J, Panos, Ralph J, Shade, David, Sternberg, Alice, Stibolt, Thomas, Stoller, James K, Tonascia, James, Wise, Robert, Yusen, Roger D, Au, David H, and Feemster, Laura C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Patient Safety ,Comparative Effectiveness Research ,Lung ,Chronic Obstructive Pulmonary Disease ,Clinical Trials and Supportive Activities ,Clinical Research ,Respiratory ,Good Health and Well Being ,Administration ,Inhalation ,Adrenal Cortex Hormones ,Adrenergic beta-2 Receptor Agonists ,Aged ,Drug Therapy ,Combination ,Female ,Humans ,Male ,Middle Aged ,Muscarinic Antagonists ,Nebulizers and Vaporizers ,Oxygen Inhalation Therapy ,Practice Guidelines as Topic ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,COPD ,guidelines ,inhaled corticosteroids ,pharmacotherapy ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundAlthough inhaled therapy reduces exacerbations among patients with COPD, the effectiveness of providing inhaled treatment per risk stratification models remains unclear.Research questionAre inhaled regimens that align with the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy associated with clinically important outcomes?Study design and methodsWe conducted secondary analyses of Long-term Oxygen Treatment Trial (LOTT) data. The trial enrolled patients with COPD with moderate resting or exertional hypoxemia between 2009 and 2015. Our exposure was the patient-reported inhaled regimen at enrollment, categorized as either aligning with, undertreating, or potentially overtreating per the 2017 GOLD strategy. Our primary composite outcome was time to death or first hospitalization for COPD. Additional outcomes included individual components of the composite outcome and time to first exacerbation. We generated multivariable Cox proportional hazard models across strata of GOLD-predicted exacerbation risk (high vs low) to estimate between-group hazard ratios for time to event outcomes. We adjusted models a priori for potential confounders, clustered by site.ResultsThe trial enrolled 738 patients (73.4% men; mean age, 68.8 years). Of the patients, 571 (77.4%) were low risk for future exacerbations. Of the patients, 233 (31.6%) reported regimens aligning with GOLD recommendations; most regimens (54.1%) potentially overtreated. During a 2.3-year median follow-up, 332 patients (44.9%) experienced the composite outcome. We found no difference in time to composite outcome or death among patients reporting regimens aligning with recommendations compared with undertreated patients. Among patients at low risk, potential overtreatment was associated with higher exacerbation risk (hazard ratio, 1.42; 95% CI, 1.09-1.87), whereas inhaled corticosteroid treatment was associated with 64% higher risk of pneumonia (incidence rate ratio, 1.64; 95% CI, 1.01-2.66).InterpretationAmong patients with COPD with moderate hypoxemia, we found no difference in clinical outcomes between inhaled regimens aligning with the 2017 GOLD strategy compared with those that were undertreated. These findings suggest the need to reevaluate the effectiveness of risk stratification model-based inhaled treatment strategies.
- Published
- 2020
32. Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.
- Author
-
Zhang, William Z, Oromendia, Clara, Kikkers, Sarah Ann, Butler, James J, O'Beirne, Sarah, Kim, Kihwan, O'Neal, Wanda K, Freeman, Christine M, Christenson, Stephanie A, Peters, Stephen P, Wells, J Michael, Doerschuk, Claire, Putcha, Nirupama, Barjaktarevic, Igor, Woodruff, Prescott G, Cooper, Christopher B, Bowler, Russell P, Comellas, Alejandro P, Criner, Gerard J, Paine, Robert, Hansel, Nadia N, Han, Meilan K, Crystal, Ronald G, Kaner, Robert J, Ballman, Karla V, Curtis, Jeffrey L, Martinez, Fernando J, and Cloonan, Suzanne M
- Subjects
Lung ,Bronchoalveolar Lavage Fluid ,Humans ,Pulmonary Disease ,Chronic Obstructive ,Disease Progression ,Iron ,Iron-Binding Proteins ,Respiratory Function Tests ,Forced Expiratory Volume ,Severity of Illness Index ,Risk Factors ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Female ,Male ,Ferritins ,Biomarkers - Abstract
Levels of iron and iron-related proteins including ferritin are higher in the lung tissue and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy controls. Whether more iron in the extracellular milieu of the lung associates with distinct clinical phenotypes of COPD, including increased exacerbation susceptibility, is unknown. We measured iron and ferritin levels in the bronchoalveolar lavage fluid (BALF) of participants enrolled in the SubPopulations and InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-study (n = 195). BALF Iron parameters were compared to systemic markers of iron availability and tested for association with FEV1 % predicted and exacerbation frequency. Exacerbations were modelled using a zero-inflated negative binomial model using age, sex, smoking, and FEV1 % predicted as clinical covariates. BALF iron and ferritin were higher in participants with COPD and in smokers without COPD when compared to non-smoker control participants but did not correlate with systemic iron markers. BALF ferritin and iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin and iron conveying a 24% and 2-fold increase in exacerbation risk, respectively. Similar associations were not observed with plasma ferritin. Increased airway iron levels may be representative of a distinct pathobiological phenomenon that results in more frequent COPD exacerbation events, contributing to disease progression in these individuals.
- Published
- 2020
33. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
- Author
-
Barnes, Hayley, Morisset, Julie, Molyneaux, Philip, Westall, Glen, Glaspole, Ian, Collard, Harold R, Collaborators, CHP Exposure Assessment, Antoniou, Katerina M, Barber, Christopher M, Behr, Jürgen, Bonella, Francesco, Corte, Tamera, Costabel, Ulrich, Cottin, Vincent, Crestani, Bruno, Dalphin, Jean-Charles, Flaherty, Kevin R, Goh, Nicole, Johannson, Kerri A, Kondoh, Yasuhiro, Lederer, David, Lee, Joyce, Maher, Toby M, Martinez, Fernando J, Morell, Ferran, Noth, Imre, Raghu, Ganesh, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, Salisbury, Margaret L, Singh, Sheetu, Selman, Moises, Strek, Mary E, Tarlo, Susan M, Tomassetti, Sara, Vancheri, Carlo, Vasakova, Martina, Wolters, Paul, and Wells, Athol
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Management of diseases and conditions ,7.3 Management and decision making ,Alveolitis ,Extrinsic Allergic ,Chronic Disease ,Consensus ,Humans ,Lung ,Tomography ,X-Ray Computed ,extrinsic allergic alveolitis ,hypersensitivity pneumonitis ,interstitial lung diseases ,CHP Exposure Assessment Collaborators ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundChronic hypersensitivity pneumonitis (CHP) is an immune-mediated interstitial lung disease (ILD) caused by inhalational exposure to environmental antigens, resulting in parenchymal fibrosis. By definition, a diagnosis of CHP assumes a history of antigen exposure, but only half of all patients eventually diagnosed with CHP will have a causative antigen identified. Individual clinician variation in eliciting a history of antigen exposure may affect the frequency and confidence of CHP diagnosis.MethodsA list of potential causative exposures were derived from a systematic review of the literature. A Delphi method was applied to an international panel of ILD experts to obtain consensus regarding technique for the elicitation of exposure to antigens relevant to a diagnosis of CHP. The consensus threshold was set at 80% agreement, and median ≤ 2, interquartile range = 0 on a 5-point Likert scale (1, strongly agree; 2, tend to agree; 3, neither agree nor disagree; 4, disagree; 5, strongly disagree).ResultsIn two rounds, 36/40 experts participated. Experts agreed on 18 exposure items to ask every patient with suspected CHP. Themes included CHP inducing exposures, features that contribute to an exposure's relevance, and quantification of a relevant exposure. Based on the results from the literature review and Delphi process, a CHP exposure assessment instrument was derived. Using cognitive interviews, the instrument was revised by patients with ILD for readability and usability.ConclusionsThis Delphi survey provides items that ILD experts agree are important to ask in all patients presenting with suspected CHP and provides basis for a systematically derived CHP exposure assessment instrument. Clinical utility of this exposure assessment instrument may be affected by different local prevalence patterns of exposures. Ongoing research is required to clinically validate these items and consider their impact in more geographically diverse settings.
- Published
- 2020
34. The Effects of Rare SERPINA1 Variants on Lung Function and Emphysema in SPIROMICS
- Author
-
Ortega, Victor E, Li, Xingnan, O’Neal, Wanda K, Lackey, Lela, Ampleford, Elizabeth, Hawkins, Gregory A, Grayeski, Philip J, Laederach, Alain, Barjaktarevic, Igor, Barr, R Graham, Cooper, Christopher, Couper, David, Han, MeiLan K, Kanner, Richard E, Kleerup, Eric C, Martinez, Fernando J, Paine, Robert, Peters, Stephen P, Pirozzi, Cheryl, Rennard, Stephen I, Woodruff, Prescott G, Hoffman, Eric A, Meyers, Deborah A, Bleecker, Eugene R, Alexis, Neil E, Anderson, Wayne H, Arjomandi, Mehrdad, Bateman, Lori A, Bhatt, Surya P, Boucher, Richard C, Bowler, Russell P, Christenson, Stephanie A, Comellas, Alejandro P, Criner, Gerard J, Crystal, Ronald G, Curtis, Jeffrey L, Doerschuk, Claire M, Dransfield, Mark T, Freeman, Christine M, Galban, Craig, Hansel, Nadia N, Hastie, Annette T, Huang, Yvonne, Kaner, Robert J, Krishnan, Jerry A, LaVange, Lisa M, Lazarus, Stephen C, Moore, Wendy C, Paulin, Laura, Putcha, Nirupama, Oelsner, Elizabeth C, Raman, Sanjeev, Tashkin, Donald P, Wells, J Michael, and Wise, Robert A
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Tobacco ,Emphysema ,Clinical Research ,Genetics ,Tobacco Smoke and Health ,Lung ,Chronic Obstructive Pulmonary Disease ,2.1 Biological and endogenous factors ,Aetiology ,Respiratory ,Adult ,Black or African American ,Aged ,Aged ,80 and over ,Female ,Forced Expiratory Volume ,Genotype ,Heterozygote ,Hispanic or Latino ,Humans ,Isoelectric Focusing ,Male ,Maximal Midexpiratory Flow Rate ,Middle Aged ,Phenotype ,Polymorphism ,Genetic ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Smoking ,Tomography ,X-Ray Computed ,Vital Capacity ,White People ,alpha 1-Antitrypsin ,chronic obstructive pulmonary disease ,alpha-1 antitrypsin ,SERPINA1 ,rare variant ,emphysema ,NHLBI Subpopulations and Intermediate Outcomes Measures in COPD Study ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
Rationale: The role of PI (protease inhibitor) type Z heterozygotes and additional rare variant genotypes in the gene encoding alpha-1 antitrypsin, SERPINA1 (serpin peptidase inhibitor, clade A, member 1), in determining chronic obstructive pulmonary disease risk and severity is controversial.Objectives: To comprehensively evaluate the effects of rare SERPINA1 variants on lung function and emphysema phenotypes in subjects with significant tobacco smoke exposure using deep gene resequencing and alpha-1 antitrypsin concentrations.Methods: DNA samples from 1,693 non-Hispanic white individuals, 385 African Americans, and 90 Hispanics with ≥20 pack-years smoking were resequenced for the identification of rare variants (allele frequency
- Published
- 2020
35. Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
- Author
-
Stott-Miller, Marni, Müllerová, Hana, Miller, Bruce, Tabberer, Maggie, Baou, Céline El, Keeley, Tom, Martinez, Fernando J, Han, Meilan, Dransfield, Mark, Hansel, Nadia N, Cooper, Christopher B, Woodruff, Prescott, Ortega, Victor E, Comellas, Alejandro P, Paine, Robert, Kanner, Richard E, Anderson, Wayne, Drummond, M Bradley, Kim, Victor, Tal-Singer, Ruth, and Lazaar, Aili L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Clinical Research ,Chronic Obstructive Pulmonary Disease ,Respiratory ,Bronchitis ,Chronic ,Female ,Humans ,Male ,Mucus ,Pulmonary Disease ,Chronic Obstructive ,Quality of Life ,Respiratory Function Tests ,Surveys and Questionnaires ,COPD ,SGRQ ,exacerbation ,CAT ,cough ,phlegm ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
BackgroundChronic cough and phlegm are frequently reported chronic obstructive pulmonary disease (COPD) symptoms. Prior research classified chronic mucus hypersecretion (CMH) based on the presence of these symptoms for ≥3 months, called chronic bronchitis (CB) if respiratory infection symptoms were present for 1-2 years (Medical Research Council [MRC] definition). We explored whether the COPD Assessment Test (CAT), a simple measure developed for routine clinical use, captures CMH populations and outcomes similarly to MRC and St. George's Respiratory Questionnaire (SGRQ) definitions.MethodsWe identified CMH in the SPIROMICS COPD cohort using (a) MRC definitions, (b) SGRQ questions for cough and phlegm (both as most/several days a week), and (c) CAT cough and phlegm questions. We determined optimal cut-points for CAT items and described exacerbation frequencies for different CMH definitions. Moderate exacerbations required a new prescription for antibiotics/oral corticosteroids or emergency department visit; severe exacerbations required hospitalization. Results were stratified by smoking status.ResultsIn a population of 1431 participants (57% male; mean FEV1% predicted 61%), 47% and 49% of evaluable participants had SGRQ- or CAT-defined CMH, respectively. A cut-point of ≥2 for cough and phlegm items defined CMH in CAT. Among SGRQ-CMH+ participants, 80% were also defined as CMH+ by the CAT. CMH+ participants were more likely to be current smokers. A higher exacerbation frequency was observed for presence of CMH+ versus CMH- in the year prior to baseline for all CMH definitions; this trend continued across 3 years of follow-up, regardless of smoking status.ConclusionItems from the CAT identified SGRQ-defined CMH, a frequent COPD trait that correlated with exacerbation frequency. The CAT is a short, simple questionnaire and a potentially valuable tool for telemedicine or real-world trials. CAT-based CMH is a novel approach for identifying clinically important characteristics in COPD that can be ascertained in these settings.
- Published
- 2020
36. Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort
- Author
-
Cooper, Christopher B, Paine, Robert, Curtis, Jeffrey L, Kanner, Richard E, Martinez, Carlos H, Meldrum, Catherine A, Bowler, Russell, O’Neal, Wanda, Hoffman, Eric A, Couper, David, Quibrera, Miguel, Criner, Gerald, Dransfield, Mark T, Han, MeiLan K, Hansel, Nadia N, Krishnan, Jerry A, Lazarus, Stephen C, Peters, Stephen P, Barr, R Graham, Martinez, Fernando J, and Woodruff, Prescott G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Tobacco Smoke and Health ,Chronic Obstructive Pulmonary Disease ,Tobacco ,Lung ,Respiratory ,Good Health and Well Being ,Cohort Studies ,Dyspnea ,Female ,Humans ,Male ,Pulmonary Disease ,Chronic Obstructive ,Surveys and Questionnaires ,disability ,frailty ,exacerbation rate ,mortality ,SPIROMICS ,SPIROMICS investigators ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology - Abstract
RationaleSome COPD patients develop extreme breathlessness, decreased exercise capacity and poor health status yet respiratory disability is poorly characterized as a distinct phenotype.ObjectiveTo define respiratory disability in COPD based on available functional measures and to determine associations with risk for exacerbations and death.MethodsWe analyzed baseline data from a multi-center observational study (SPIROMICS). This analysis includes 2332 participants (472 with severe COPD, 991 with mild/moderate COPD, 726 smokers without airflow obstruction and 143 non-smoking controls).MeasurementsWe defined respiratory disability by ≥4 of 7 criteria: mMRC dyspnea scale ≥3; Veterans Specific Activity Questionnaire 60; COPD Assessment Test >20; fatigue (FACIT-F Trial Outcome Index)
- Published
- 2020
37. Erratum: Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum].
- Author
-
Barjaktarevic, Igor, Buhr, Russell G, Wang, Xiaoyan, Hu, Scott, Couper, David, Anderson, Wayne, Kanner, Richard E, Paine III, Robert, Bhatt, Surya P, Bhakta, Nirav R, Arjomandi, Mehrdad, Kaner, Robert J, Pirozzi, Cheryl S, Curtis, Jeffrey L, O'Neal, Wanda K, Woodruff, Prescott G, Han, MeiLan K, Martinez, Fernando J, Hansel, Nadia, Wells, James Michael, Ortega, Victor E, Hoffman, Eric, Doerschuk, Claire M, Kim, Victor, Dransfield, Mark T, Drummond, M Bradley, Bowler, Russell, Criner, Gerard, Christenson, Stephanie A, Ronish, Bonnie, Peters, Stephen, Krishnan, Jerry A, Tashkin, Donald, and Cooper, Christopher
- Subjects
Cardiorespiratory Medicine and Haematology ,Respiratory System - Abstract
[This corrects the article DOI: 10.2147/COPD.S220164.].
- Published
- 2020
38. Metoprolol for the Prevention of Acute Exacerbations of COPD
- Author
-
Dransfield, Mark T, Voelker, Helen, Bhatt, Surya P, Brenner, Keith, Casaburi, Richard, Come, Carolyn E, Cooper, J Allen D, Criner, Gerard J, Curtis, Jeffrey L, Han, MeiLan K, Hatipoğlu, Umur, Helgeson, Erika S, Jain, Vipul V, Kalhan, Ravi, Kaminsky, David, Kaner, Robert, Kunisaki, Ken M, Lambert, Allison A, Lammi, Matthew R, Lindberg, Sarah, Make, Barry J, Martinez, Fernando J, McEvoy, Charlene, Panos, Ralph J, Reed, Robert M, Scanlon, Paul D, Sciurba, Frank C, Smith, Anthony, Sriram, Peruvemba S, Stringer, William W, Weingarten, Jeremy A, Wells, J Michael, Westfall, Elizabeth, Lazarus, Stephen C, and Connett, John E
- Subjects
Clinical Trials and Supportive Activities ,Chronic Obstructive Pulmonary Disease ,Lung ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Respiratory ,Adrenergic beta-1 Receptor Antagonists ,Aged ,Aged ,80 and over ,Disease Progression ,Female ,Forced Expiratory Volume ,Hospitalization ,Humans ,Kaplan-Meier Estimate ,Male ,Metoprolol ,Middle Aged ,Prospective Studies ,Pulmonary Disease ,Chronic Obstructive ,Treatment Failure ,BLOCK COPD Trial Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundObservational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.MethodsIn this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo. All the patients had a clinical history of COPD, along with moderate airflow limitation and an increased risk of exacerbations, as evidenced by a history of exacerbations during the previous year or the prescribed use of supplemental oxygen. We excluded patients who were already taking a beta-blocker or who had an established indication for the use of such drugs. The primary end point was the time until the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, depending on the adjusted dose of metoprolol.ResultsA total of 532 patients underwent randomization. The mean (±SD) age of the patients was 65.0±7.8 years; the mean forced expiratory volume in 1 second (FEV1) was 41.1±16.3% of the predicted value. The trial was stopped early because of futility with respect to the primary end point and safety concerns. There was no significant between-group difference in the median time until the first exacerbation, which was 202 days in the metoprolol group and 222 days in the placebo group (hazard ratio for metoprolol vs. placebo, 1.05; 95% confidence interval [CI], 0.84 to 1.32; P = 0.66). Metoprolol was associated with a higher risk of exacerbation leading to hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83). The frequency of side effects that were possibly related to metoprolol was similar in the two groups, as was the overall rate of nonrespiratory serious adverse events. During the treatment period, there were 11 deaths in the metoprolol group and 5 in the placebo group.ConclusionsAmong patients with moderate or severe COPD who did not have an established indication for beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol. (Funded by the Department of Defense; BLOCK COPD ClinicalTrials.gov number, NCT02587351.).
- Published
- 2019
39. Relationship between diffusion capacity and small airway abnormality in COPDGene.
- Author
-
Criner, Rachel N, Hatt, Charles R, Galbán, Craig J, Kazerooni, Ella A, Lynch, David A, McCormack, Meredith C, Casaburi, Richard, MacIntyre, Neil R, Make, Barry J, Martinez, Fernando J, Labaki, Wassim W, Curtis, Jeffrey L, and Han, Mei Lan K
- Subjects
Humans ,Pulmonary Disease ,Chronic Obstructive ,Pulmonary Emphysema ,Airway Obstruction ,Carbon Monoxide ,Tomography ,X-Ray Computed ,Respiratory Function Tests ,Pulmonary Diffusing Capacity ,Severity of Illness Index ,Multivariate Analysis ,Regression Analysis ,Retrospective Studies ,Cohort Studies ,Aged ,Middle Aged ,Female ,Male ,Bronchioles ,Airway Remodeling ,Chronic obstructive pulmonary disease ,Diffusing capacity of the lung ,Parametric response mapping ,Small airways disease ,Pulmonary Disease ,Chronic Obstructive ,Tomography ,X-Ray Computed ,Respiratory System ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences - Abstract
Impaired single breath carbon monoxide diffusing capacity (DLCO) is associated with emphysema. Small airways disease (SAD) may be a precursor lesion to emphysema, but the relationship between SAD and DLCO is undescribed. We hypothesized that in mild COPD, functional SAD (fSAD) defined by computed tomography (CT) and Parametric Response Mapping methodology would correlate with impaired DLCO. Using data from ever-smokers in the COPDGene cohort, we established that fSAD correlated significantly with lower DLCO among both non-obstructed and GOLD 1-2 subjects. The relationship between DLCO with CT-defined emphysema was present in all GOLD stages, but most prominent in severe disease. TRIAL REGISTRATION: NCT00608764. Registry: COPDGene. Registered 06 February 2008, retrospectively registered.
- Published
- 2019
40. COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.
- Author
-
Lowe, Katherine E, Regan, Elizabeth A, Anzueto, Antonio, Austin, Erin, Austin, John HM, Beaty, Terri H, Benos, Panayiotis V, Benway, Christopher J, Bhatt, Surya P, Bleecker, Eugene R, Bodduluri, Sandeep, Bon, Jessica, Boriek, Aladin M, Boueiz, Adel Re, Bowler, Russell P, Budoff, Matthew, Casaburi, Richard, Castaldi, Peter J, Charbonnier, Jean-Paul, Cho, Michael H, Comellas, Alejandro, Conrad, Douglas, Costa Davis, Corinne, Criner, Gerard J, Curran-Everett, Douglas, Curtis, Jeffrey L, DeMeo, Dawn L, Diaz, Alejandro A, Dransfield, Mark T, Dy, Jennifer G, Fawzy, Ashraf, Fleming, Margaret, Flenaugh, Eric L, Foreman, Marilyn G, Fortis, Spyridon, Gebrekristos, Hirut, Grant, Sarah, Grenier, Philippe A, Gu, Tian, Gupta, Abhya, Han, MeiLan K, Hanania, Nicola A, Hansel, Nadia N, Hayden, Lystra P, Hersh, Craig P, Hobbs, Brian D, Hoffman, Eric A, Hogg, James C, Hokanson, John E, Hoth, Karin F, Hsiao, Albert, Humphries, Stephen, Jacobs, Kathleen, Jacobson, Francine L, Kazerooni, Ella A, Kim, Victor, Kim, Woo Jin, Kinney, Gregory L, Koegler, Harald, Lutz, Sharon M, Lynch, David A, MacIntye, Neil R, Make, Barry J, Marchetti, Nathaniel, Martinez, Fernando J, Maselli, Diego J, Mathews, Anne M, McCormack, Meredith C, McDonald, Merry-Lynn N, McEvoy, Charlene E, Moll, Matthew, Molye, Sarah S, Murray, Susan, Nath, Hrudaya, Newell, John D, Occhipinti, Mariaelena, Paoletti, Matteo, Parekh, Trisha, Pistolesi, Massimo, Pratte, Katherine A, Putcha, Nirupama, Ragland, Margaret, Reinhardt, Joseph M, Rennard, Stephen I, Rosiello, Richard A, Ross, James C, Rossiter, Harry B, Ruczinski, Ingo, San Jose Estepar, Raul, Sciurba, Frank C, Sieren, Jessica C, Singh, Harjinder, Soler, Xavier, Steiner, Robert M, Strand, Matthew J, Stringer, William W, Tal-Singer, Ruth, Thomashow, Byron, Vegas Sánchez-Ferrero, Gonzalo, and Walsh, John W
- Subjects
COPD Genetic Epidemiology study ,preserved ratio-impaired spirometry ,COPD diagnosis ,COPD diagnosis ,COPDGene ,GOLD ,Global initiative for chronic Obstructive Lung Dis ,PRISm ,chronic obstructive pulmonary disease ,copd ,preserved ratio-impaired spirometry ,spirometry ,Prevention ,Tobacco Smoke and Health ,Tobacco ,Lung ,Chronic Obstructive Pulmonary Disease ,Biomedical Imaging ,Clinical Research ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Respiratory ,Good Health and Well Being ,COPD ,COPD Genetic Epidemiology study ,Global initiative for chronic Obstructive Lung Disease - Abstract
BackgroundChronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality. Present-day diagnostic criteria are largely based solely on spirometric criteria. Accumulating evidence has identified a substantial number of individuals without spirometric evidence of COPD who suffer from respiratory symptoms and/or increased morbidity and mortality. There is a clear need for an expanded definition of COPD that is linked to physiologic, structural (computed tomography [CT]) and clinical evidence of disease. Using data from the COPD Genetic Epidemiology study (COPDGene®), we hypothesized that an integrated approach that includes environmental exposure, clinical symptoms, chest CT imaging and spirometry better defines disease and captures the likelihood of progression of respiratory obstruction and mortality.MethodsFour key disease characteristics - environmental exposure (cigarette smoking), clinical symptoms (dyspnea and/or chronic bronchitis), chest CT imaging abnormalities (emphysema, gas trapping and/or airway wall thickening), and abnormal spirometry - were evaluated in a group of 8784 current and former smokers who were participants in COPDGene® Phase 1. Using these 4 disease characteristics, 8 categories of participants were identified and evaluated for odds of spirometric disease progression (FEV1 > 350 ml loss over 5 years), and the hazard ratio for all-cause mortality was examined.ResultsUsing smokers without symptoms, CT imaging abnormalities or airflow obstruction as the reference population, individuals were classified as Possible COPD, Probable COPD and Definite COPD. Current Global initiative for obstructive Lung Disease (GOLD) criteria would diagnose 4062 (46%) of the 8784 study participants with COPD. The proposed COPDGene® 2019 diagnostic criteria would add an additional 3144 participants. Under the new criteria, 82% of the 8784 study participants would be diagnosed with Possible, Probable or Definite COPD. These COPD groups showed increased risk of disease progression and mortality. Mortality increased in patients as the number of their COPD characteristics increased, with a maximum hazard ratio for all cause-mortality of 5.18 (95% confidence interval [CI]: 4.15-6.48) in those with all 4 disease characteristics.ConclusionsA substantial portion of smokers with respiratory symptoms and imaging abnormalities do not manifest spirometric obstruction as defined by population normals. These individuals are at significant risk of death and spirometric disease progression. We propose to redefine the diagnosis of COPD through an integrated approach using environmental exposure, clinical symptoms, CT imaging and spirometric criteria. These expanded criteria offer the potential to stimulate both current and future interventions that could slow or halt disease progression in patients before disability or irreversible lung structural changes develop.
- Published
- 2019
41. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD
- Author
-
Alexis, Neil E., Anderson, Wayne H., Arjomandi, Mehrdad, Barjaktarevic, Igor, Barr, R. Graham, Basta, Patricia, Bateman, Lori A., Bhatt, Surya P., Bleecker, Eugene R., Boucher, Richard C., Bowler, Russell P., Christenson, Stephanie A., Comellas, Alejandro P., Cooper, Christopher B., Couper, David J., Criner, Gerard J., Crystal, Ronald G., Curtis, Jeffrey L., Doerschuk, Claire M., Dransfield, Mark T., Drummond, Brad, Freeman, Christine M., Galban, Craig, Han, MeiLan K., Hansel, Nadia N., Hastie, Annette T., Hoffman, Eric A., Huang, Yvonne, Kaner, Robert J., Kanner, Richard E., Kleerup, Eric C., Krishnan, Jerry A., LaVange, Lisa M., Lazarus, Stephen C., Martinez, Fernando J., Meyers, Deborah A., Moore, Wendy C., Newell, John D., Jr., Paine, Robert, III, Paulin, Laura, Peters, Stephen P., Pirozzi, Cheryl, Putcha, Nirupama, Oelsner, Elizabeth C., O’Neal, Wanda K., Ortega, Victor E., Raman, Sanjeev, Rennard, Stephen I., Tashkin, Donald P., Wells, J. Michael, Wise, Robert A., Woodruff, Prescott G., Fortis, Spyridon, Quibrera, Pedro M., Dransfield, Mark B., Dolezal, Brett A., Kim, Victor, Barjaktarevic, Igor Z., and Couper, David
- Published
- 2023
- Full Text
- View/download PDF
42. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort
- Author
-
LeMaster, W. Blake, Quibrera, P. Miguel, Couper, David, Tashkin, Donald P., Bleecker, Eugene R., Doerschuk, Claire M., Ortega, Victor E., Cooper, Christopher, Han, MeiLan K., Woodruff, Prescott G., O’Neal, Wanda K., Anderson, Wayne H., Alexis, Neil E., Bowler, Russell P., Barr, R. Graham, Kaner, Robert J., Dransfield, Mark T., Paine, Robert, III, Kim, Victor, Curtis, Jeffrey L., Martinez, Fernando J., Hastie, Annette T., and Barjaktarevic, Igor
- Published
- 2023
- Full Text
- View/download PDF
43. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study
- Author
-
Chaudhary, Muhammad F A, Hoffman, Eric A, Guo, Junfeng, Comellas, Alejandro P, Newell, John D, Jr, Nagpal, Prashant, Fortis, Spyridon, Christensen, Gary E, Gerard, Sarah E, Pan, Yue, Wang, Di, Abtin, Fereidoun, Barjaktarevic, Igor Z, Barr, R Graham, Bhatt, Surya P, Bodduluri, Sandeep, Cooper, Christopher B, Gravens-Mueller, Lisa, Han, MeiLan K, Kazerooni, Ella A, Martinez, Fernando J, Menchaca, Martha G, Ortega, Victor E, III, Robert Paine, Schroeder, Joyce D, Woodruff, Prescott G, and Reinhardt, Joseph M
- Published
- 2023
- Full Text
- View/download PDF
44. Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study
- Author
-
Allen, Richard J, Oldham, Justin M, Jenkins, David A, Leavy, Olivia C, Guillen-Guio, Beatriz, Melbourne, Carl A, Ma, Shwu-Fan, Jou, Jonathan, Kim, John S, Fahy, William A, Oballa, Eunice, Hubbard, Richard B, Navaratnam, Vidya, Braybrooke, Rebecca, Saini, Gauri, Roach, Katy M, Tobin, Martin D, Hirani, Nik, Whyte, Moira K B, Kaminski, Naftali, Zhang, Yingze, Martinez, Fernando J, Linderholm, Angela L, Adegunsoye, Ayodeji, Strek, Mary E, Maher, Toby M, Molyneaux, Philip L, Flores, Carlos, Noth, Imre, Gisli Jenkins, R, and Wain, Louise V
- Published
- 2023
- Full Text
- View/download PDF
45. Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts
- Author
-
Choi, Bina, Adan, Najma, Doyle, Tracy J., San José Estépar, Ruben, Harmouche, Rola, Humphries, Stephen M., Moll, Matthew, Cho, Michael H., Putman, Rachel K., Hunninghake, Gary M., Kalhan, Ravi, Liu, Gabrielle Y., Diaz, Alejandro A., Mason, Stefanie E., Rahaghi, Farbod N., Pistenmaa, Carrie L., Enzer, Nicholas, Poynton, Clare, Sánchez-Ferrero, Gonzalo Vegas, Ross, James C., Lynch, David A., Martinez, Fernando J., Han, MeiLan K., Bowler, Russell P., Wilson, David O., Rosas, Ivan O., Washko, George R., San José Estépar, Raúl, and Ash, Samuel Y.
- Published
- 2023
- Full Text
- View/download PDF
46. Biological Age, Chronological Age and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis
- Author
-
Pugashetti, Janelle Vu, primary, Kim, John S., additional, Bose, Swaraj, additional, Adegunsoye, Ayodeji, additional, Linderholm, Angela L, additional, Chen, Ching-Hsien, additional, Strek, Mary E., additional, Flaherty, Kevin R., additional, Murray, Susan, additional, Newton, Chad A., additional, Alqalyoobi, Shehabaldin, additional, Ma, Shwu-Fan, additional, Mychaleckyj, Josyf C., additional, Bowler, Russell P., additional, Han, MeiLan K., additional, Curtis, Jeffrey L., additional, Martinez, Fernando J., additional, Smith, Jennifer A, additional, Noth, Imre, additional, and Oldham, Justin M., additional
- Published
- 2024
- Full Text
- View/download PDF
47. Association of Ground Glass Opacities with Systemic Inflammation and Progression of Emphysema
- Author
-
Fortis, Spyridon, primary, Guo, Junfeng, additional, Nagpal, Prashant, additional, Chaudhary, Muhammad F. A., additional, Newell Jr., John D, additional, Gerard, Sarah E, additional, Han, MeiLan K., additional, Kazerooni, Ella A., additional, Martinez, Fernando J., additional, Barjaktarevic, Igor Z., additional, Barr, R Graham, additional, Bodduluri, Sandeep, additional, Paine III, Robert, additional, Awan, Hira A., additional, Schroeder, Joyce D., additional, Gravens-Mueller, Lisa D., additional, Ortega, Victor E., additional, Anderson, Wayne H, additional, Cooper, Christopher B., additional, Couper, David, additional, Woodruff, Prescott G., additional, Bowler, Russell P., additional, Bhatt, Surya P, additional, Hoffman, Eric A., additional, Reinhardt, Joseph M, additional, and Comellas, Alejandro P., additional
- Published
- 2024
- Full Text
- View/download PDF
48. AERIFY-1/-2: 2 phase 3 randomised controlled trials of itepekimab in former smokers with moderate-to-severe COPD
- Author
-
Rabe, Klaus F., primary, Martinez, Fernando J., additional, Bhatt, Surya P., additional, Kawayama, Tomotaka, additional, Cosio, Borja G., additional, Mroz, Robert M., additional, Boomsma, Maarten M., additional, Goulaouic, Helene, additional, Nivens, Michael C., additional, Djandji, Michel, additional, Soler, Xavier, additional, Liu, Ying, additional, Kosloski, Matthew P., additional, Xu, Christine R., additional, Amin, Nikhil, additional, Staudinger, Heribert, additional, Lederer, David J., additional, and Abdulai, Raolat M., additional
- Published
- 2024
- Full Text
- View/download PDF
49. Air Pollution Exposure and Interstitial Lung Features in SPIROMICS Participants with COPD
- Author
-
Baddour, Nicolas A., primary, Paulin, Laura M, additional, Gassett, Amanda J., additional, Woo, Han, additional, Hoffman, Eric A., additional, Newell, John D, additional, Woodruff, Prescott G., additional, Pirozzi, Cheryl S., additional, Barjaktarevic, Igor, additional, Barr, R Graham, additional, O'Neal, Wanda, additional, Han, MeiLan K., additional, Martinez, Fernando J., additional, Peters, Stephen P., additional, Hastie, Annette T., additional, Hansel, Nadia N, additional, Ortega, Victor E., additional, Kaufman, Joel D., additional, and Sack, Coralynn S., additional
- Published
- 2024
- Full Text
- View/download PDF
50. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis
- Author
-
Bardsley, Samuel, Criner, Gerard J., Halpin, David M.G., Han, MeiLan K., Hanania, Nicola A., Hill, David, Lange, Peter, Lipson, David A., Martinez, Fernando J., Midwinter, Dawn, Siler, Thomas M., Singh, Dave, Wise, Robert A., van Zyl-Smit, Richard N., and Berkman, Neville
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.